Your browser doesn't support javascript.
Strength and durability of antibody responses to BNT162b2 and CoronaVac.
Cowling, Benjamin J; Wong, Irene O L; Shiu, Eunice Y C; Lai, Amber Y T; Cheng, Samuel M S; Chaothai, Sara; Kwan, Kelvin K H; Martín-Sánchez, Mario; Poon, Leo L M; Ip, Dennis K M; Leung, Gabriel M; Leung, Nancy H L; Peiris, J S Malik.
  • Cowling BJ; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administ
  • Wong IOL; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
  • Shiu EYC; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
  • Lai AYT; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
  • Cheng SMS; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
  • Chaothai S; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
  • Kwan KKH; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
  • Martín-Sánchez M; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
  • Poon LLM; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hon
  • Ip DKM; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
  • Leung GM; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administ
  • Leung NHL; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administ
  • Peiris JSM; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hon
Vaccine ; 40(32): 4312-4317, 2022 07 30.
Article in English | MEDLINE | ID: covidwho-1886118
ABSTRACT
We studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine (Sinovac) and BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). We compared rates of antibody waning over time using an enzyme-linked immunosorbent assay for spike receptor binding domain and a surrogate virus neutralization test. We found stronger and more durable antibody responses to two doses of the mRNA vaccine, and slightly stronger initial antibody responses to each vaccine in younger adults and women. The weaker and less durable responses following CoronaVac support earlier provision of third doses to persons who previously received two doses of this vaccine.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: BNT162 Vaccine / Antibody Formation Topics: Vaccines Limits: Adult / Female / Humans Language: English Journal: Vaccine Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: BNT162 Vaccine / Antibody Formation Topics: Vaccines Limits: Adult / Female / Humans Language: English Journal: Vaccine Year: 2022 Document Type: Article